<DOC>
	<DOCNO>NCT01143779</DOCNO>
	<brief_summary>The goal clinical research study learn image solution , [ F-18 ] -fluoro-L-thymidine ( FLT ) , use positron emission tomography ( PET ) scan , help doctor well see change growth tumor body . Researchers want learn FLT-PET scan show early response chemotherapy .</brief_summary>
	<brief_title>FLT-PET Imaging Biomarker With Temsirolimus , Topotecan , Bortezomib</brief_title>
	<detailed_description>FLT-PET Scan : An FLT-PET scan us FLT solution , contain small amount radioactive material , help locate cancer cell inside body . This scan may help doctor find solid tumor well learn tumor grow fast grow . This information could use help predict cancer respond treatment . Study Visits : Within 2 week Day 1 Cycle 1 Days 19 21 Cycle 1 , FLT-PET scan . For least 4 hour FLT-PET scan , must eat drink anything . You receive FLT solution vein . The FLT solution mildly radioactive material . The radioactive nature solution allow scanner `` see '' certain place body . After injection , need rest quietly time scan . The amount rest time may vary , prepared wait 60 minute . During scan , lie flat back table . After solution inject vein , PET scanner take picture radioactive solution move body collect various site body . By watch solution travel body study solution collect , researcher learn status disease body . The scan may last 40-60 minute . Your vital sign ( blood pressure , heart rate , temperature , breathe rate ) measure injection FLT solution , 30 minute injection , PET scan . You allow leave 30 minute scan , vital sign acceptable . Length Study : You study second FLT-PET scan . You take study early intolerable side effect study doctor think best interest . This investigational study . The FLT solution FDA approve commercially available . At time , FLT solution use research . Up 5 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>1 . Patients enrol Protocol 20080425 : `` A Phase I Study Temsirolimus , Topotecan , Bortezomib Patients Advanced Malignancy '' Protocol 20120061 : `` A Phase I Trial Bevacizumab , Temsirolimus Alone Combination Valproic Acid Cetuximab Patients Advanced Malignancy '' eligible . These patient must meet inclusion exclusion criterion protocol . 2 . Women childbearing potential ( defined woman postmenopausal 12 month previous surgical sterilization ) men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day last dose . 3 . Ability understand willingness sign write informed consent document . 4 . Patients must least 18 year age 1 . Pregnant breastfeed woman . 2 . History hypersensitivity 3'deoxy3'18Ffluorothymidine ( 18F FLT ) component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Malignancy</keyword>
	<keyword>FLT-PET Scan</keyword>
	<keyword>[ F-18 ] -fluoro-L-thymidine</keyword>
	<keyword>FLT</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>PET</keyword>
	<keyword>Imaging Biomarker</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Bortezomib</keyword>
</DOC>